Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Wenliang Dong, Min Chen, Suping Niu, Bianzhen Wang, Lin Xia, Jiaxue Wang, Tiantian Shen, Qian Wang, Jie Lv, Gang Liu, Huaying Fan, Zhenwei Xie, Fan Xie, Youzhong an, Qingshan Zheng, Huiying Rao, Haifeng Song & Yi Fang. (2022) Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial. Expert Opinion on Biological Therapy 22:2, pages 253-262.
Read now
Read now
Yanli Wang, Zhenyue Gao, Zhengzhi Liu, Guangwen Liu, Xinyao Qu, Jiahui Chen, Xinran Ren, Zhongnan Xu & Haimiao Yang. (2022) A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers. Expert Opinion on Biological Therapy 22:2, pages 225-234.
Read now
Read now
Articles from other publishers (22)
Blaise Pasquiers, Salih Benamara, Mathieu Felices, David Ternant, Xavier Declèves & Alicja Puszkiel. (2023) Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab. Pharmaceutics 15:8, pages 2129.
Crossref
Crossref
Ammar Almaaytah. (2023) A Review of the Non-clinical and Clinical Requirements for the performance of a comparability exercise for Bevacizumab biosimilars. Research Journal of Pharmacy and Technology, pages 3499-3506.
Crossref
Crossref
Anum Jalil, James Wert, Akriti Gupta Jain & Sarfraz Ahmad. 2023. Computational Methods in Drug Discovery and Repurposing for Cancer Therapy. Computational Methods in Drug Discovery and Repurposing for Cancer Therapy
387
402
.
Tanios S Bekaii-Saab, Sigrid Balser, Ragna Lohmann, Hasan Daoud, Bernd Liedert & Dorothee Schliephake. (2022) Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer. Colorectal Cancer.
Crossref
Crossref
Lijun Xie, Ying Zhu, Zuojun Liang, Yuqing Zhao, Sufeng Zhou, Juan Chen, Hongwen Zhang, Sijia Ding, Lu Wang & Feng Shao. (2022) Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin®) in Healthy Chinese Subjects. European Journal of Drug Metabolism and Pharmacokinetics 47:3, pages 309-317.
Crossref
Crossref
Angela Sinn, Fernanda García‐Alvarado, Veronica Gonzalez, Camino Huerga & Felicitas Bullo. (2021) A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers. British Journal of Clinical Pharmacology 88:3, pages 1063-1073.
Crossref
Crossref
Matthew Hummel, Tjerk Bosje, Andrew Shaw, Mark Shiyao Liu, Abhijit Barve, Mudgal Kothekar, Mark A. Socinski & Cornelius F. Waller. (2021) A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab. Journal of Cancer Research and Clinical Oncology 148:2, pages 487-496.
Crossref
Crossref
Edward S. Kim, Sigrid Balser, Klaus B. Rohr, Ragna Lohmann, Bernd Liedert & Dorothee Schliephake. (2022) Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC. JTO Clinical and Research Reports 3:1, pages 100248.
Crossref
Crossref
Takashi Eto, Yuji Karasuyama, Verónica González & Ana Del Campo García. (2021) A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers. Cancer Chemotherapy and Pharmacology 88:4, pages 713-722.
Crossref
Crossref
Martin Demarchi, Pierre Coliat, Philippe Barthelemy, Roland Schott, Meher BenAbdelghani, Michael Kim, Jocelyn Chung Shii Hii, Peggy Feyaerts, Felicia Rui Xia Ang, Marie Paule Derde, Filip Deforce, Thierry Petit, Chris Schwabe, Chris Wynne, Lisa Soyeon Park & Xavier Pivot. (2021) A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab. PLOS ONE 16:9, pages e0248222.
Crossref
Crossref
Xiaoxue Zhu, Hongjie Qian, Jixuan Sun, Min Wu, Chen Yu, Yanhua Ding, Xiaodi Zhang, Katherine Chai & Xiaojiao Li. (2021) A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers. Cancer Chemotherapy and Pharmacology 88:3, pages 465-474.
Crossref
Crossref
Luis Pérez Díaz, Susana Millán, Nuran Chaban, Ana del Campo & Eduardo Spitzer. (2021) Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. Future Oncology 17:19, pages 2529-2544.
Crossref
Crossref
Kai Huang, Linling Que, Ying Ding, Nannan Chu, Zhenzhong Qian, Yunfei Shi, Wei Qin, Zhenni Li, Yuanxin Chen, Xianghong Gu, Jiakun Wang, Lin Zhang, Jisheng Zhang, Xiangyang Zhu, Yongmin Yang, Yuan Tang & Qing He. (2021) A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects. Frontiers in Pharmacology 12.
Crossref
Crossref
Donghoon Shin, Yoon Jung Lee, Jihye Choi, Dahyoung Lee, Minjeong Park & Magdalena Petkova. (2020) A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers. Cancer Chemotherapy and Pharmacology 86:4, pages 567-575.
Crossref
Crossref
Inderjeet Singh, Ronak Patel, Akash Patel & Vinu Jose. (2020) A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men. Cancer Chemotherapy and Pharmacology 86:2, pages 193-202.
Crossref
Crossref
Ya-nan Liu, Jie Huang, Can Guo, Shuang Yang, Ling Ye, Shu-ting Wu, Xing-fei Zhang, Xiao-yan Yang, Cui-cui Han, Qi Pei, Lu Huang, Qing-nan He & Guo-ping Yang. (2020) A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects. Cancer Chemotherapy and Pharmacology 85:3, pages 555-562.
Crossref
Crossref
Jin Wang, Lu Qi, Long Liu, Zejuan Wang, Gang Chen, Yu Wang, Xiaona Liu, Ying Liu, Huijuan Liu, Yuanxu Tong, Chen Liu, Chunpu Lei & Xinghe Wang. (2019) A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers. Frontiers in Pharmacology 10.
Crossref
Crossref
Chien-Lung Tu, Yi-Lin Wang, Teh-Min Hu & Li-Feng Hsu. (2019) Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?. BioDrugs 33:4, pages 437-446.
Crossref
Crossref
Joyson J. Karakunnel, Nam Bui, Latha Palaniappan, Keith T. Schmidt, Kenneth W. Mahaffey, Briggs Morrison, William D. Figg & Shivaani Kummar. (2018) Reviewing the role of healthy volunteer studies in drug development. Journal of Translational Medicine 16:1.
Crossref
Crossref
Chris Wynne, Christian Schwabe, Sonica Sachdeva Batra, Luis Lopez-Lazaro & Suresh Kankanwadi. (2018)
A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin
®
(EU and US) in healthy male subjects
. British Journal of Clinical Pharmacology 84:10, pages 2352-2364.
Crossref
Crossref
Hong Zhang, Qingmei Li, Xiaoxue Zhu, Cuiyun Li, Xiaojiao Li, Chengjiao Liu, Yue Hu, Guiling Chen, Haijing Wei, Jing Wang, Zhenwei Shen & Yanhua Ding. (2018) Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects. Cancer Chemotherapy and Pharmacology 82:4, pages 615-623.
Crossref
Crossref
Sophie I. E. Knahl, Benjamin Lang, Frank Fleischer & Meinhard Kieser. (2018) A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs. European Journal of Clinical Pharmacology 74:5, pages 549-559.
Crossref
Crossref